GLP-1
Metabolic peptide
Effect index
+0.61
95% CrI
[0.44, 0.77]
Effect index +0.61, 95% confidence interval 0.44 to 0.77
GLP-1 refers to glucagon-like peptide-1 and the medicines that act on its pathway. People report using it for appetite regulation and metabolic outcomes.
What is measured
The effect index reflects self-reported metabolic outcomes among people who already use a GLP-1 medicine, read against their own baseline with a 95 percent credible interval.
What is established
The metabolic signal is strong and the interval is tight, which the larger reporting population supports. The result is stable across the record.
What is not established
This entry measures self-reported outcomes, not a head-to-head clinical trial. It does not establish dosing, long-term safety, or suitability for any individual. It is not medical advice. Decisions about a GLP-1 medicine belong with a physician. We never supply or prescribe.
Evidence record
Studies in this entry
Each study record is a component of the effect index above. All numbers are illustrative.
Appetite-regulation subgroup analysis
A pre-specified subgroup reporting appetite outcomes showed an effect consistent with the full population.
Effect
+0.57
n
540
Self-reported metabolic outcomes among current GLP-1 users
A large reporting population recorded metabolic outcomes against their own baseline. The signal is strong and stable.
Effect
+0.61
n
1240
Illustrative sample